The remaining two patients progressed rapidly—an H3K27M mutant diffuse midline glioma with PDGFRA mutation treated with ponatinib and then regorafenib, and an MB with FGFR3 mutation given pazopanib, ifosfamide and doxorubicin. This evidence concerns the gene PDGFRA and diffuse midline glioma.